P H A R M A G R A M

...an educational memo from your Therapeutics Committee

December, 2000

 

Nationwide Shortage of Fentanyl:

 

Due to production problems, fentanyl is in extremely short supply. Over the past few weeks the fentanyl inventory reached a critically low level, resulting in many prescribers of fentanyl being asked to consider alternative analgesics or using patient-controlled analgesia PCA) pumps instead of frequent prn injections. The Pharmacy at St. Francis Medical Center was able to procure a drug supply and was able to meet all of the patients’ analgesic needs. The shortage is expected to continue into January. Barring any further manufacturing or distribution problems, adequate supply of fentanyl should remain available.

 

Emergency Code Cart Medication Changes:

 

Reflecting new ACLS guidelines, several adjustments to the medication contents of the code carts will be made effective December 15th. Isoproterenol and bretylium will be removed and vasopressin and amiodarone will be added. Vasopressin, administered as a 40 unit IV bolus, will offer an alternative to epinephrine. Amiodarone will be packaged on the carts with a dextrose solution for drug dilution and IV line flush. During a cardiac arrest, amiodarone 300mg should be diluted to 20ml and bolused intravenously over 1-2 minutes. Diazepam (Valium) will be removed based on a Joint Commission recommendation.

 

Alosetron (Lotronex) Withdrawn from the Market:

 

Alosetron, a drug indicated for irritable bowel syndrome in women, has been associated with some severe intestinal damage and 5 deaths are now reported with its use. The manufacturer, Glaxo Wellcome, decided to withdraw the drug based on the FDA surveillance reports. After FDA approval in February, alosetron was reviewed by the Pharmacy and Therapeutics Committee and decided against adding it to the Formulary.

 

Tirofiban (Aggrastat) Removed from the Formulary:

Abciximab (ReoPro) was shown to be superior to tirofiban in the recently reported TARGET study, which compared these two parenteral antiplatelet drugs in coronary artery interventions. Based on these results and limited use, tirofiban was removed from the Formulary. The two other intravenous antiplatelet drugs, abciximab (ReoPro) and eptifibatide (Integrilin) will continue to be available.

Avoid Med Errors – Dose Fosphenytoin (Cerebyx) As Phenytoin Equivalence

If you prescribe fosphenytoin, dose it as if it were phenytoin, which the manufacturer refers to as phenytoin equivalence or PE. For example, if you would normally be giving 1000 MG of phenytoin as a loading dose but want to use fosphenytoin, then order fosphenytoin as 1000 MG PE. Be sure to specify ‘PE" to avoid a pharmacy call for confirmation of the dose.

Report Adverse Drug Events on the ADE Hotline – 655-6805